Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study
Authors
Keywords
-
Journal
Hepatology International
Volume 16, Issue 5, Pages 1170-1178
Publisher
Springer Science and Business Media LLC
Online
2022-08-25
DOI
10.1007/s12072-022-10398-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A retrospective multicenter study
- (2022) Sabrina Welland et al. Liver Cancer
- Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
- (2021) Myung Ji Goh et al. Liver Cancer
- Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA
- (2021) Amit G Singal et al. Future Oncology
- Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
- (2021) M. Rimini et al. ESMO Open
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
- (2020) Jaekyung Cheon et al. Liver Cancer
- Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy
- (2020) Masako Shomura et al. Cancers
- Australian recommendations for the management of hepatocellular carcinoma: a consensus statement
- (2020) John S Lubel et al. MEDICAL JOURNAL OF AUSTRALIA
- Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
- (2019) Max W. Sung et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
- (2019) Shuntaro Obi et al. Hepatology International
- Lenvatinib for the treatment of HCC: A single institute experience.
- (2019) San-Chi Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis
- (2018) Atsushi Hiraoka et al. Cancer Medicine
- Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study
- (2016) Adam Doyle et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Epidemiology of Hepatocellular Carcinoma
- (2013) Sahil Mittal et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2013) Ju-Yeon Cho et al. LIVER INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More